Certican derives Successful Result

.

Certican derives Successful Result

Surely, it was a good news for Novartis that it has been able to have positive result of its phase III clinical study of immune system drug known as Certican. The news was worth getting happy, as it has been found that the Swiss pharmaceutical company was trying to get everything right for last two years.

In addition, it has been said that the project is considered to be the biggest project that has been taken out by the company with regard to liver transplant. It has been found that the drug is quite effective in improving renal function among patients.

The data about the same was revealed at the meeting of American Association for the Study of Liver Diseases (AASLD), which is in its 63rd year. The drug, which has already received approval from European health authorities, is likely to get approval from the US health regulators Food and Drug Administration by the end of 2012.

"These results showed that treatment with Certican with reduced tacrolimus led to a clinically relevant retention of renal function compared to standard tacrolimus, with no compromise in rejection", said John Fung, who is positioned as director at Transplantation Center. It is expected that the drug is able to provide benefit to adults suffering from liver problem.


Latest News

PPIC’s Poll Reveals Californians Divided in Opinion on Climate Change Impacting
Chairman Says the Boeing Company May have to Move Some Operations Overseas if Ex
Facebook Second Quarter Earnings Surpass Analysts’ Expectations but Growing Expe
Overcharging Scandal Takes a Toll on Whole Foods Earnings
Yelp Trims Third Quarter Earnings Forecast Also Announces Departure of Its Chair
Solvay, the Belgian Chemical Group to Acquire U.S. Cytec for $5.5 billion
Reports Say Amazon Suggests Dividing Airspace into Zones for Delivery Drones
Federal Reserve Expected to Stay Focused on Rate Hike Plan in September
Oil Prices Drop Near Four-Month Low as Supply Glut and Chinese Economy Increases
Reportedly A.G. Lafley to Pass Reigns of P&G CEO to David Taylor
Baidu Profits in Second Quarter Offset by Higher Expenses
Economists Predict Solid Revenue Growth for Vermont